Catalent creates development and clinical services business unit
The new development and clinical services business unit brings together the New Jersey firm\'s analytical, science and regulatory consulting services, formerly in its sterile technologies segment, with its clinical supply services business, formerly in the packaging services segment.
The new development and clinical services business unit brings together the New Jersey firm's analytical, science and regulatory consulting services, formerly in its sterile technologies segment, with its clinical supply services business, formerly in the packaging services segment.
Scott Houlton has been appointed as group president of the new segment. He joins on 31 August from Aptuit, a global provider of development services, where he was chief operating officer. Prior to this he was president of Aptuit's clinical packaging business.
The company says the new division will build upon its expertise in supporting the development and testing of drugs and biologics through scientific, regulatory and clinical trial supply chain services.
Catalent's drugs services extend from first steps in characterising a drug molecule through to delivery to the investigator site and the final submission of regulatory filings.
Catalent's biologics offerings include advanced bioanalytical services, GPEx technology and cell-line development services, biomanufacturing and cold chain distribution for clinical trial materials.
The new division will provide drugs and biologics with global regulatory consultancy and support, respiratory delivery formulation, development and manufacture, plus early phase injectables manufacture.
John Chiminski, president and ceo of Catalent, said: "I expect the development and clinical services segment to bring even more value to our customers through a sharpened focus and an integrated approach to solving the challenges our r&d customers face, and believe that this will result in significant new growth for the segment."